Blott Peter J 4
4 · VALEANT PHARMACEUTICALS INTERNATIONAL · Filed Oct 20, 2010
Insider Transaction Report
Form 4
Blott Peter J
EVP & CFO
Transactions
- Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−26,136→ 0 totalExercise: $16.76Exp: 2013-06-30→ Common Stock (26,136 underlying) - Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−13,500→ 0 totalExercise: $18.55Exp: 2013-11-04→ Common Stock (13,500 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2010-09-28−4,180→ 0 totalExercise: $23.92Exp: 2014-11-26→ Common Stock (4,180 underlying) - Disposition to Issuer
Incentive Stock Option (right to buy)
2010-09-28−20,268→ 0 totalExercise: $14.80Exp: 2017-10-30→ Common Stock (20,268 underlying) - Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−15,820→ 0 totalExercise: $23.92Exp: 2014-11-26→ Common Stock (15,820 underlying) - Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−97,948→ 0 totalExercise: $38.47Exp: 2017-03-03→ Common Stock (97,948 underlying) - Disposition to Issuer
Common Stock
2010-09-28−216,889→ 0 total - Disposition to Issuer
Incentive Stock Option (right to buy)
2010-09-28−23,864→ 0 totalExercise: $16.76Exp: 2013-06-30→ Common Stock (23,864 underlying) - Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−34,000→ 0 totalExercise: $17.72Exp: 2015-11-01→ Common Stock (34,000 underlying) - Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−45,000→ 0 totalExercise: $18.68Exp: 2016-10-31→ Common Stock (45,000 underlying) - Disposition to Issuer
Non-qualified Stock Option (right to buy)
2010-09-28−29,732→ 0 totalExercise: $14.80Exp: 2017-10-30→ Common Stock (29,732 underlying)
Footnotes (8)
- [F1]216,889 restricted stock units disposed pursuant to merger agreement between issuer and, among others, Biovail Corporation in exchange for 386,258 shares of Valeant Pharmaceuticals International Inc. common stock. The fair market value of Valeant Pharmaceuticals International, Inc. on the effective date of the merger was $26.00 per share.
- [F2]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 139,886 shares of Valeant Pharmaceuticals International, Inc. common stock for $5.99 per share.
- [F3]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 95,124 shares of Valeant Pharmaceuticals International, Inc. common stock for $6.33 per share.
- [F4]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 125,900 shares of Valeant Pharmaceuticals International, Inc. common stock for $6.68 per share.
- [F5]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 139,887 shares of Valeant Pharmaceuticals International, Inc. common stock for $5.29 per share.
- [F6]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 37,769 shares of Valeant Pharmaceuticals International, Inc. common stock for $6.63 per share.
- [F7]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 55,953 shares of Valeant Pharmaceuticals International, Inc. common stock for $8.55 per share.
- [F8]This option was assumed by Valeant Pharmaceuticals International, Inc. in the merger and replaced with an option to purchase 274,037 shares of Valeant Pharmaceuticals International, Inc. common stock for $13.75 per share.